UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$438M |
| 2 |
Lockheed Martin
LMT
|
+$402M |
| 3 |
TAL Education Group
TAL
|
+$294M |
| 4 |
Microsoft
MSFT
|
+$269M |
| 5 |
Wells Fargo
WFC
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$384M |
| 2 |
Adobe
ADBE
|
+$372M |
| 3 |
Veeva Systems
VEEV
|
+$342M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$289M |
| 5 |
Global Payments
GPN
|
+$287M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.1% |
| 2 | Consumer Discretionary | 13.57% |
| 3 | Healthcare | 12.46% |
| 4 | Financials | 11.55% |
| 5 | Communication Services | 9.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Helix Energy Solutions
HLX
$1.47B
| $829K | ﹤0.01% |
197,498
+26,735
| +16% | +$89.3K |
|
|
TBIO
2027
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $829K | ﹤0.01% |
45,000
+7,300
| +19% | +$131K |
|
|
YMAB
2028
DELISTED
Y-mAbs Therapeutics
YMAB
| $829K | ﹤0.01% |
16,749
| – | – |
|
2029
Gogo Inc
GOGO
$472M
| $828K | ﹤0.01% |
+86,011
| New | +$852K |
|
2030
iShares MSCI Turkey ETF
TUR
$218M
| $828K | ﹤0.01% |
+31,164
| New | +$680K |
|
2031
Amphastar Pharmaceuticals
AMPH
$875M
| $826K | ﹤0.01% |
41,087
| – | – |
|
2032
Oceaneering
OII
$5.01B
| $822K | ﹤0.01% |
103,358
-13,256
| -11% | -$77.4K |
|
2033
Enterprise Financial Services Corp
EFSC
$2.38B
| $819K | ﹤0.01% |
23,439
| – | – |
|
2034
Mativ Holdings
MATV
$709M
| $813K | ﹤0.01% |
20,214
| – | – |
|
2035
National Beverage
FIZZ
$2.94B
| $811K | ﹤0.01% |
19,104
+674
| +4% | +$29K |
|
2036
National Bank Holdings
NBHC
$1.9B
| $809K | ﹤0.01% |
24,706
-259,526
| -91% | -$8.23M |
|
2037
First Busey Corp
BUSE
$2.55B
| $809K | ﹤0.01% |
37,553
+2,942
| +9% | +$57.7K |
|
2038
CoreCivic
CXW
$3.38B
| $805K | ﹤0.01% |
122,917
-47,849
| -28% | -$344K |
|
2039
Scholar Rock
SRRK
$6.27B
| $802K | ﹤0.01% |
16,530
+4,100
| +33% | +$149K |
|
2040
Adtran
ADTN
$649M
| $802K | ﹤0.01% |
54,294
| – | – |
|
2041
LeMaitre Vascular
LMAT
$1.87B
| $802K | ﹤0.01% |
19,798
| – | – |
|
2042
PAR Technology
PAR
$744M
| $797K | ﹤0.01% |
+12,700
| New | +$623K |
|
|
TSC
2043
DELISTED
TriState Capital Holdings, Inc.
TSC
| $797K | ﹤0.01% |
45,824
| – | – |
|
2044
Alphatec Holdings
ATEC
$1.46B
| $793K | ﹤0.01% |
+54,600
| New | +$577K |
|
2045
Inogen
INGN
$169M
| $792K | ﹤0.01% |
17,735
-3,304
| -16% | -$114K |
|
2046
Conduent
CNDT
$239M
| $790K | ﹤0.01% |
164,651
-2,517
| -2% | -$10.5K |
|
2047
BancFirst
BANF
$3.79B
| $790K | ﹤0.01% |
13,462
| – | – |
|
2048
SiriusPoint
SPNT
$2.64B
| $786K | ﹤0.01% |
82,526
+19,159
| +30% | +$167K |
|
2049
York Water
YORW
$510M
| $784K | ﹤0.01% |
16,818
| – | – |
|
2050
Precigen
PGEN
$2.58B
| $784K | ﹤0.01% |
76,831
-11,200
| -13% | -$72.6K |
|
Similar funds
UBS AM's Q4 2020 Portfolio in Review
As of Q4 2020, UBS AM held 2,632 positions worth $213B, up 15% from $186B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
UBS AM's Q4 2020 filing shows 139 new, 1,393 increased, 625 reduced and 83 closed positions. Its largest new stake was Maravai LifeSciences: 3,763,012 shares worth $106M. The largest sale was Mastercard, an estimated $384M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- UBS AM's largest Q4 2020 buy was Maravai LifeSciences: 3,763,012 shares worth $106M.
- UBS AM added most to Apple in Q4 2020, an estimated $438M increase.
- UBS AM's biggest Q4 2020 reduction was Mastercard, cutting an estimated $384M.
- UBS AM fully exited State Street Technology Select Sector SPDR ETF in Q4 2020, selling an estimated $115M.
- UBS AM's ten largest holdings make up 23% of its $213B portfolio in Q4 2020.
- UBS AM opened 139 new positions and closed 83 in Q4 2020.
- UBS AM's portfolio value rose 15% quarter-over-quarter to $213B.
Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.